About iovance biotherapeutics inc. - IOVA
Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
IOVA At a Glance
Iovance Biotherapeutics, Inc.
825 Industrial Road
San Carlos, California 94070
| Phone | 1-650-260-7120 | Revenue | 263.50M | |
| Industry | Biotechnology | Net Income | -390,978,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 60.603% | |
| Fiscal Year-end | 12 / 2026 | Employees | 975 | |
| View SEC Filings |
IOVA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.702 |
| Price to Book Ratio | 1.61 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.075 |
| Enterprise Value to Sales | 2.763 |
| Total Debt to Enterprise Value | 0.068 |
IOVA Efficiency
| Revenue/Employee | 270,258.462 |
| Income Per Employee | -401,003.077 |
| Receivables Turnover | 3.196 |
| Total Asset Turnover | 0.289 |
IOVA Liquidity
| Current Ratio | 3.20 |
| Quick Ratio | 2.826 |
| Cash Ratio | 2.146 |
IOVA Profitability
| Gross Margin | 20.637 |
| Operating Margin | -151.123 |
| Pretax Margin | -149.164 |
| Net Margin | -148.378 |
| Return on Assets | -42.88 |
| Return on Equity | -55.498 |
| Return on Total Capital | -52.268 |
| Return on Invested Capital | -52.174 |
IOVA Capital Structure
| Total Debt to Total Equity | 7.078 |
| Total Debt to Total Capital | 6.61 |
| Total Debt to Total Assets | 5.415 |
| Long-Term Debt to Equity | 6.356 |
| Long-Term Debt to Total Capital | 5.936 |